In honor of National Colorectal Cancer Awareness Month, Today.com interviewed physicians about symptoms that should never be ignored. “People are maybe sometimes uncomfortable about talking about that part of their body,” Dr. Jennifer Inra, a gastroenterologist at Brigham and Women’s Hospital in Boston, told Today.com. Still, the best way to address the risk is to
Vedolizumab demonstrated significantly greater efficacy as induction and maintenance therapy for UC than placebo in patients naive to TNF antagonists and patients with TNF antagonist failure. There were numerically greater treatment differences at Week 6 among patients receiving vedolizumab who were naive to TNF antagonists than patients with TNF antagonist failure. An AGA Reading Room
